UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~September 1421, 2014

Calypte Biomedical Corporation

(Exact name of registrant as specified in its charter)

Delaware	000-20985	06-1226727
(State or other jurisdiction)	(Commission File Number)	(I.R.S. Employer Identification)
of Incorporation)

15875 SW 72nd Ave, Portland, OR 97224

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (503) 726-2227

N/A

(Former name or former address, if changed since last report)

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))

Item 31.0301 ~~Material~~Entry ~~Modification~~into toa ~~Rights~~Material ofDefinitive ~~Security Holders~~Agreement

OnThe ~~March~~Registrant ~~14,~~and ~~2014,~~David ~~the~~Khidasheli ~~Registrant~~have ~~amended~~entered ~~its~~into ~~Restated~~a ~~Certificate~~Stock ofPurchase ~~Incorporation~~Agreement todated September 21, 2014 (ithe “Khidasheli Agreement”) ~~increase~~providing for the ~~number~~issuance to Mr. Khidasheli of ~~authorized~~52,966,666 shares of the Registrant’s Common Stock ~~from~~(the ~~800~~“Khidasheli Shares”),~~000~~ at a purchase price of $0.03 per share, in consideration of $1,589,000 in advances that Mr. Khidasheli made to 2the Registrant during the three-year period ended December 31,~~400~~ 2013. These advances include $1,000,000 ~~and~~advanced ~~(ii)~~pursuant ~~decrease~~to ~~the~~a ~~par~~Memorandum ~~value~~ of ~~the~~Understanding ~~Common~~dated ~~Stock~~October to10, ~~$0.005.~~2011 Abetween ~~copy~~Mr. ofKhidasheli and the Registrant’s ~~Certificate~~(the of“MOU”). ~~Amendment~~The ofentry ~~Restated~~into ~~Certificate~~the ofMOU ~~Incorporation~~was isreported ~~attached~~previously ~~hereto~~on asa ~~Exhibit~~Form 998-K filed on October 14, 2011.1.

Item 53.0702 ~~Submission~~Unregistered ofSales ~~Matters to a Vote~~ of ~~Security~~Equity ~~Holders~~Securities

OnPursuant ~~March~~to 14the Khidasheli Agreement, ~~2014~~the Registrant has issued the Khidasheli Shares to Mr. Khidasheli. In addition, pursuant to a ~~special~~Stock ~~meeting~~Purchase ofAgreement ~~stockholders~~dated ~~was~~September ~~held~~21, to2014 ~~consider~~between the ~~amendment~~Registrant and Carolina Lupascu, the Registrant issued to Ms. Lupascu 416,666 shares of the Registrant’s ~~Restated~~Common ~~Certificate~~Stock (the “Lupascu Shares”) at a purchase price of ~~Incorporation~~$0.03 ~~described~~per share in ~~Item~~consideration 3of an advance of $12,500 that Ms.03 ~~above~~Lupascu made to the Registrant in January 2013. The ~~stockholders~~Khidasheli ~~approved~~Shares and the ~~amendment~~Lupascu byShares were issued in offshore transactions in reliance upon Regulation S promulgated under the ~~following~~Securities ~~vote:~~Act of 1933.

For	Against	Abstain	Broker Non-Votes
409,730,480	6,250,881	577,434	0

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	~~Certificate~~Stock ofPurchase ~~Amendment~~Agreement ofdated ~~Restated~~September ~~Certificate~~21, of2014 ~~Incorporation~~between the Registrant and David Khidasheli.

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~March~~ 18September 24, 2014

Calypte Biomedical Corporation By: /s/ Adel Karas Adel Karas President, ~~Chairman of the Board~~ and Chief Executive Officer

Filing Compare · CALYPTE BIOMEDICAL CORP